Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals — Investor Presentation (March 2021)

25 slides from Zynerba Pharmaceuticals's investor presentation, Mar 10, 2021

  1. Slide 1: Corporate Overview March 2021

    Corporate Overview March 2021

  2. Slide 2: Forward-Looking Statements

    Forward - Looking Statements 2 © 2020 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. trademarks are property of their respective owners. THE S

  3. Slide 3: Zynerba Pharmaceuticals: A Rare/Near-Rare Neuropsychiatric Company

    Zynerba Pharmaceuticals (NASDAQ: ZYNE) 3 A Rare/Near - Rare Neuropsychiatric Company • Deep pipeline targeting high unmet medical needs; translating into multi - billion dollar market opportunity with Zygel Œ (Cannabidiol Gel) • Focused on completing development of Zygel in Fragile X Syndrome (FXS)

  4. Slide 4: Deep Clinical Pipeline & Near-term Milestones

    Deep Clinical Pipeline & Near - term Milestones 4 Zygel Cannabidiol Gel *Orphan Drug and Fast Track designation **Orphan Drug designation Expected Milestones Review trial design and protocol with FDA in 1H21; initiate confirmatory pivotal trial before the end of 2021 Discuss Phase 2 results and regu

  5. Slide 5: Zygel (ZYN002) Cannabidiol Gel

    Neuropsych Indications Differentiated Formulation delivers Cannabidiol through the epidermis and into the circulatory system Zygel (ZYN002) Cannabidiol Gel 5 Unique Mechanism of Action First & only patent - protected (2038), permeation - enhanced, pharmaceutically - produced cannabidiol gel Transder

  6. Slide 6: Fragile X Syndrome

    6 • Rare genetic developmental disability • Leading known cause of both inherited intellectual disability and ASD • No approved drugs indicated for FXS • Symptoms linked to deficiencies in the endocannabinoid system (ECS) • Mutation impacts FMR1 gene and causes ECS dysregulation, causing core cognit

  7. Slide 7: CONNECT-FX Trial Design

    CONNECT - FX Trial Design 7 C linical study O f Ca NN abidiol in Childr E n and Adoles C en T s with F ragile X (CONNECT - FX) Zygel (n=110; 92*) 250 mg daily 500 mg daily (weight - based dose) Placebo (n=102; 77*) Mirrored Zygel administration Two week placebo period, followed by 12 weeks of treatm

  8. Slide 8: CONNECT-FX Endpoints and Data Collected

    CONNECT - FX 8 • Primary endpoint: • Change from baseline to end of treatment in ABC - C FXS Social Avoidance subscale • Key secondary endpoints: • Change from baseline to end of the treatment in • ABC - C FXS Irritability subscale score • ABC - C FXS Socially Unresponsive/Lethargic subscale score •

  9. Slide 9: CONNECT-FX Results: ≥90% FMR1 Methylation

    9 9 CONNECT - FX Results: ≥90% FMR1 Methylation Consistent Improvements Observed with Zygel vs. Placebo Caregiver reported behavioral change Clinician reported improvements in behavior Clinically meaningful improvements in behavior Primary endpoint Caregiver Global Impression of Change Any Improveme

  10. Slide 10: CONNECT-FX: Safety

    CONNECT - FX: Safety 10 • Zygel was very well tolerated • No serious or severe adverse events reported during the trial • All treatment - emergent adverse events (TEAEs; any event, whether unrelated or related to study drug) were mild or moderate • Most common treatment - related TEAE: application s

  11. Slide 11: The Path Forward For Zygel in FXS

    The Path Forward For Zygel in FXS 11 • Zynerba plans to conduct a single double blind, placebo controlled pivotal trial in patients with a highly methylated FMR1 gene to confirm results seen in CONNECT - FX responders • If results are positive, we believe this trial will be sufficient to support an

  12. Slide 12: Autism Spectrum Disorder

    12 • Near - rare disorder • Symptoms include irritability; anxiety, restricted, repetitive patterns of behavior; impairments in social communication; deficits in verbal and non - verbal communication; deficits in developing, understanding and maintaining relationships • Most diagnosed after age 4; c

  13. Slide 13: BRIGHT Phase 2 Trial in ASD

    BRIGHT Phase 2 Trial in ASD 13 Open - La B el Tole R ab I lity and Efficacy Study of ZYN002 Administered as a Transdermal G el to C H ildren and Adolescen T s with Autism Spectrum Disorder 37 pts with moderate - to - severe ASD enrolled Three through 17 years of age Screening Zygel 14 Weeks Weight b

  14. Slide 14: Results of BRIGHT Phase 2 Trial

    14 14 Results of BRIGHT Phase 2 Trial Autism symptom frequency and impact Parental stress Qualitative caregiver assessments Severity of anxiety Primary efficacy objective ABC - C subscales % improvement Irritability: 39.1% ( p <0.0001*) Inappropriate Speech: 42.5% ( p =0.0002*) Stereotypy: 39.1% ( p

  15. Slide 15: Well Tolerated Safety Profile in BRIGHT Trial in ASD

    • Well tolerated; consistent with previously released data • Fewer than half of patients experienced an adverse event (AE); most were mild and transient • Only 14% of patients experienced a treatment - related AE • All application site - related • No severe or serious AEs reported during the trial 1

  16. Slide 16: Next Steps in ASD Program

    Next Steps in ASD Program 16 • In 1H2021, Zynerba intends to discuss data supporting the potential efficacy of Zygel in ASD, including the results of the Phase 2 BRIGHT trial, with the FDA to determine the regulatory path forward • Present additional data at future medical meetings

  17. Slide 17: 22q11.2 Deletion Syndrome

    17 • Rare disorder; most common contiguous gene deletion syndrome • Midline condition with abnormalities affecting palate, face, heart and other organs; surgically corrected in infancy • Neuropsychiatric illnesses (anxiety disorders, ASD) and learning disabilities common • 22q associated with increa

  18. Slide 18: INSPIRE Phase 2 Trial in 22q

    INSPIRE Phase 2 Trial in 22q 18 Target: 20 patients Six through 17 years of age Screening Zygel 14 Weeks Weight based dosing: 14 Weeks 250 mg to 500 mg daily Efficacy assessments (week 14 vs baseline) include: • Aberrant Behavior Checklist - Community (ABC - C) • Anxiety, Depression and Mood Scale (

  19. Slide 19: Developmental and Epileptic Encephalopathies

    19 • Group of rare / ultra rare childhood - onset epilepsies with impaired or regressed developmental progress • Cognitive impairment, psychiatric problems, and behavioral disturbances are phenotypic • Medically fragile population • Comorbidities include cerebral palsy, chronic respiratory infection

  20. Slide 20: BELIEVE Phase 2 Trial in DEE

    BELIEVE Phase 2 Trial in DEE 20 Open La B el Study to Assess the Safety and E fficacy of ZYN002 Administered as a Transderma L Gel to Ch I ldren and Adol E scents with De V elopmental and E pileptic Encephalopathy 48 patients enrolled Three through 17 years of age Screening Maintenance 22 Weeks Titr

  21. Slide 21: Results of BELIEVE Phase 2 Trial

    21 21 Results of BELIEVE Phase 2 Trial Clinically Meaningful Improvements in FIAS / TCS and QoL vs. Baseline ≥35% and ≥50% responders Reductions in seizures in patients with ASD Improved Sleep Qualitative assessments Primary efficacy objective Median % Reductions in Seizures Month 3 (n=33): 44% Mont

  22. Slide 22: BELIEVE Safety: Zygel Well Tolerated over 12 Months

    22 • Tolerability profile consistent with the safety database for Zygel • Most treatment - emergent adverse events (TEAEs) (any event, whether unrelated or related to study drug) were mild or moderate • Two SAEs deemed possibly drug - related (LRTI and status epilepticus) • No drug - related clinica

  23. Slide 23: Financial Strength

    Financial Strength 23 • Clean balance sheet • No debt, 41.3 M shares outstanding (as of March 5, 2020) • Cash and cash equivalent position of $59.2M as of December 31, 2020 • From January 1, 2021 to February 9, 2021 we raised net proceeds of $42.2 million through the sale of 10.2 million shares of e

  24. Slide 24: Deep Clinical Pipeline & Near-term Milestones

    Deep Clinical Pipeline & Near - term Milestones 24 Zygel Cannabidiol Gel *Orphan Drug and Fast Track designation **Orphan Drug designation Expected Milestones Review trial design and protocol with FDA in 1H21; initiate confirmatory pivotal trial before the end of 2021 Discuss Phase 2 results and reg

  25. Slide 25: Corporate Overview March 2021

    Corporate Overview March 2021

Zynerba Pharmaceuticals — Investor Presentation (March 2021) on 6ix